ATE321559T1 - Impfstoff auf einem plasmid beruhend zur behandlung von atherosclerosis - Google Patents

Impfstoff auf einem plasmid beruhend zur behandlung von atherosclerosis

Info

Publication number
ATE321559T1
ATE321559T1 AT97924549T AT97924549T ATE321559T1 AT E321559 T1 ATE321559 T1 AT E321559T1 AT 97924549 T AT97924549 T AT 97924549T AT 97924549 T AT97924549 T AT 97924549T AT E321559 T1 ATE321559 T1 AT E321559T1
Authority
AT
Austria
Prior art keywords
atherosclerosis
plasmid
treatment
cetp
vaccine
Prior art date
Application number
AT97924549T
Other languages
English (en)
Inventor
Lawrence J Thomas
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Application granted granted Critical
Publication of ATE321559T1 publication Critical patent/ATE321559T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97924549T 1996-05-01 1997-05-01 Impfstoff auf einem plasmid beruhend zur behandlung von atherosclerosis ATE321559T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64071396A 1996-05-01 1996-05-01
US80296797A 1997-02-21 1997-02-21

Publications (1)

Publication Number Publication Date
ATE321559T1 true ATE321559T1 (de) 2006-04-15

Family

ID=27093614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97924549T ATE321559T1 (de) 1996-05-01 1997-05-01 Impfstoff auf einem plasmid beruhend zur behandlung von atherosclerosis

Country Status (8)

Country Link
EP (1) EP0914427B1 (de)
JP (1) JP2001508760A (de)
AT (1) ATE321559T1 (de)
AU (1) AU721729B2 (de)
CA (1) CA2250428A1 (de)
DE (1) DE69735591T2 (de)
ES (1) ES2262179T3 (de)
WO (1) WO1997041227A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831881B1 (de) 1995-06-06 2003-03-12 Avant Immunotherapeutics, Inc. Cetp zur erhöhung des hdl-cholesterol-gehalts
CA2302778A1 (en) * 1997-09-19 1999-04-01 Monsanto Company Dna vaccination against cholesterol ester transfer protein in the treatment of atherosclerosis
JP2001520204A (ja) * 1997-10-20 2001-10-30 アヴァント イムノセラピューティクス，インコーポレーテッド コレステリルエステル運搬タンパク質（ｃｅｔｐ）活性を調節するための異種ｃｅｔｐ
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
EA003634B1 (ru) 1998-10-05 2003-08-28 Фармэкса А/С Новые способы терапевтической вакцинации
CZ20011896A3 (cs) * 1998-12-19 2002-01-16 Ml Laboratories Plc Imunogenní prostředek a protilátka
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
WO2001012661A2 (en) * 1999-08-16 2001-02-22 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
AU2002321526A1 (en) * 2001-08-22 2003-03-10 Cambridge Theranostics Ltd Means for treatment of atherosclerosis
US7148028B2 (en) 2001-08-22 2006-12-12 Cambridge Theranostics Ltd. Methods and means relating to atherosclerosis
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US20060276400A1 (en) * 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
WO2009125231A2 (en) * 2008-04-10 2009-10-15 Thrombosis Research Institute Anti-atheroma vaccine
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410022B1 (en) * 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity

Also Published As

Publication number Publication date
DE69735591D1 (de) 2006-05-18
JP2001508760A (ja) 2001-07-03
CA2250428A1 (en) 1997-11-06
EP0914427B1 (de) 2006-03-29
EP0914427A1 (de) 1999-05-12
AU721729B2 (en) 2000-07-13
ES2262179T3 (es) 2006-11-16
DE69735591T2 (de) 2007-04-05
AU2994697A (en) 1997-11-19
WO1997041227A1 (en) 1997-11-06

Similar Documents

Publication Publication Date Title
DE69735591D1 (de) Impfstoff auf einem plasmid beruhend zur behandlung von atherosclerosis
FI945549A (fi) Deoksiribonukleaasin puhdistetut muodot
HUP9901254A2 (hu) Nemdendrites szerkezetű gerincet alkotó peptid hordozó
AU4951196A (en) Vaccines for plague
ATE233101T1 (de) Polynukleotide vakzine gegen den papilloma virus
GB8912330D0 (en) Live vaccines
ATE342916T1 (de) Synthetische hiv gag gene
ATE365053T1 (de) Auf hefe basierte vehikel zur abgabe
ES2043890T3 (es) Nuevo uso medico.
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
ATE352634T1 (de) Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
NO904538L (no) Kimaere glykoproteiner inneholdende immunogene segmenter av humant parainfluensavirus type 3.
DE69518760D1 (de) Wachstumsdifferenzierungsfaktor-12
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
DE69635472D1 (de) Impfstoff gegen Geflügelkokzidose
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
DE3789525D1 (de) Das F-Protein vom AIDS-Virus enthaltender Impfstoff.
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
MX9702769A (es) Mejoras en una linea de celulas sustentable o estable para la produccion de vacunas para la enfermedad de marek.
Lasky et al. Production of an HSV subunit vaccine by genetically engineered mammalian cell lines.
Gharavi Molecular cloning of the human lipoxygenase gene
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
ITCT920024A1 (it) Denti-salva 1
Gurd The social impact of communication technologies in health care: intervention and patient empowerment
ITCT920025A1 (it) "denti-salva 2"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties